Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene er større end risiciene ved immunisering af kvæg med Ibraxion for at reducere de kliniske tegn på IBR og nedsætte udskillelsen af markvirus.
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Ibraxion are greater than any risks to immunise cattle to reduce the clinical signs of IBR and reduce field virus excretion.